Article
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2022
Mogenet Alice, Barlesi Fabrice, Besse Benjamin, Michiels Stefan, Karimi Maryam, Tran-Dien Alicia, Girard Nicolas, Mazieres Julien, Audigier-Valette Clarisse, Locatelli-Sanchez Myriam, Kamal Maud, Gestraud Pierre, Hamza Abderaouf, Jacquet Alexandra, Jimenez Marta, Yara Sabrina, Greillier Laurent, Bertucci François, Planchard David, Soria Jean-Charles, Bieche Ivan, Tomasini Pascale
Abstract excerpt
INTRODUCTION: Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several mechanisms: genomic heterogeneity, blood-tumor barrier, and the brain-specific microenvironment. We conducted a study using data from the SAFIR02-LUNG trial. The primary objective was to compare the...
Topics
Join the communities discussing this publication.